Furthermore, we performed immunohistochemistry (IHC) of the representative signatures (CD44 and GZMK) of the CD8+ Tem49 to evaluate tumor infiltration in tissue samples from therapy-naïve CRC patients. This evidence concerns the gene CD44 and neoplasm.